Home / Research library / Survodutide
Compound guide
Survodutide: what the research covers
The other glucagon and GLP-1 dual agonist in this catalogue, and the one whose clinical programme has concentrated on the liver rather than on body weight alone.
What Survodutide is
Survodutide is an acylated peptide agonist at both the glucagon receptor and the GLP-1 receptor, in a ratio weighted towards glucagon relative to some other compounds in the class. Albumin binding through the fatty acid chain gives it a long circulating life.
The design logic is the same as mazdutide: the glucagon arm contributes hepatic fat oxidation and energy expenditure, the GLP-1 arm contributes satiety and offsets the glycaemic effect of glucagon receptor activation. Where the two compounds differ is in the balance between the arms, and that difference is the substance of any comparison between them.
It is in clinical development, and the programme that has attracted most attention is in metabolic dysfunction-associated steatohepatitis rather than in obesity — a liver endpoint rather than a weight endpoint.
Why the liver endpoint matters mechanistically
Glucagon receptors are densely expressed in hepatocytes, and glucagon receptor activation drives fatty acid oxidation there. A dual agonist weighted towards glucagon is therefore predicted to act on hepatic lipid content through a route that a pure incretin agonist does not have, and the reported histological improvement in steatohepatitis trials is the kind of evidence that distinguishes mechanism from general weight-related benefit.
For a laboratory this makes survodutide a useful comparator in hepatocyte work specifically: an effect present with survodutide and absent with a GLP-1-only agonist points at the glucagon receptor, and the two compounds together make that inference available. Running it against mazdutide addresses the finer question of how much the ratio matters.
Research strands cover receptor potency ratios, hepatic lipid handling and steatosis models, energy expenditure, and the pharmacokinetics of albumin-bound acylated peptides.
How Amino Club supplies it
Supplied lyophilised in sealed vials as Survodutide and released against the Certificate of Analysis for its own batch; the lab testing page documents what that covers.
Handling follows the pattern for long acylated peptides: surface activity means no vigorous agitation, aggregation behaviour is concentration dependent, solutions are kept cold and used promptly, and freeze-thaw cycling is avoided. The sealed powder is stored below −18 °C. Diluents are under reconstitution supplies, with preservative-free water usually preferred where a cell-based readout follows.
Related reading
Survodutide sits in the metabolic research peptides group with mazdutide, cagrilintide, AOD-9604, 5-Amino-1MQ and AICAR.
Every guide is indexed in the research library. Certificates and storage are covered on the FAQ, quantity pricing through bulk and wholesale.
Research use only
Survodutide supplied by Amino Club is a laboratory reference material. It is not a medicine, not a supplement, and not for human or veterinary use, and no dosing guidance or administration protocol is provided. The full terms are in the research use policy.